Evidence map›Paper›PMID 41243079›Full record

ArticleAIDS and behavior2026

Assessing Demand for Long-Acting Injectable PrEP and Emerging PrEP Options for HIV Prevention in Australia: Results from a Cross-Sectional Survey of Men Who have Sex with Men.

Curtis Chan, Heather-Marie Schmidt, Jason J Ong, Warittha Tieosapjaroen, Andrew E Grulich, Nittaya Phanuphak, Edwina J Wright, Bella Bushby, Lei Zhang, Benjamin R Bavinton

Abstract read
PubMed Publisher
In one paragraph

Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Curtis ChanKirby Institute, UNSW Sydney, Sydney, Australia. cchan@kirby.unsw.edu.au.ORCID http://orcid.org/0000-0002-9581-1011
Heather-Marie SchmidtUNAIDS, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-2629-6407
Jason J OngMelbourne Sexual Health Centre, Alfred Health, Melbourne, Australia.ORCID http://orcid.org/0000-0001-5784-7403
Warittha TieosapjaroenKirby Institute, UNSW Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0001-9712-9262
Andrew E GrulichKirby Institute, UNSW Sydney, Sydney, Australia.
Nittaya PhanuphakInstitute of HIV Research and Innovation, Bangkok, Thailand.ORCID http://orcid.org/0000-0002-0036-3165
Edwina J WrightDepartment of Infectious Diseases, The Alfred Hospital, Melbourne, Australia.ORCID http://orcid.org/0000-0001-8626-782X
Bella BushbyKirby Institute, UNSW Sydney, Sydney, Australia.ORCID https://orcid.org/0009-0004-0446-1354
Lei ZhangMelbourne Sexual Health Centre, Alfred Health, Melbourne, Australia.ORCID http://orcid.org/0000-0003-2343-084X
Benjamin R BavintonKirby Institute, UNSW Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0001-5834-8278

Funding

Department of Health and Aged Care, Australian Government Department of Health and Aged Care, Australian GovernmentMAC AIDS Fund MAC AIDS FundNSW Ministry of Health NSW Ministry of HealthViiV Healthcare ViiV HealthcareWorld Health Organization World Health Organization
6 · The paper itself

Abstract

Long-acting injectable Cabotegravir (CAB-LA) received regulatory approval in Australia but is not available for prevention. This online cross-sectional study of 1,687 gay, bisexual, and other men who have sex with men (GBMSM) in Australia between May to November 2022 assessed interest in and preference for CAB-LA and other existing and hypothetical PrEP options. When asked for their top preference, the most preferred options were monthly oral pills (28.2%), followed by six-monthly injections (24.6%), removable implants (15.5%), daily oral (14.0%), event-driven oral (13.4%), and CAB-LA (3.9%). Common potential reasons to like CAB-LA included not having to remember to take pills (65.0%), protection against HIV (63.8%), and longer-term protection compared to other methods (46.9%). Common concerns included not knowing enough about CAB-LA yet (46.7%), cost may be unaffordable (44.6%), and potential side effects (n = 547, 32.4%). There were 654 (40.3%) participants who would want long-acting PrEP injections if they could switch back and forth between other forms of PrEP. Interest in using CAB-LA was associated with younger age (aOR = 0.98, 95%CI = 0.97-0.99), having ever taken PrEP (aOR = 2.06, 95%CI = 1.48-2.88), having 11 or more sexual partners in the last 6 months (aOR = 1.65, 95%CI = 1.25-2.17), believing some friends or sex partners are taking PrEP (aOR = 1.58, 95%CI = 1.18-2.11), reporting wanting to try CAB-LA if it was more effective than oral PrEP (aOR = 2.05, 95%CI = 1.48-2.86), or believing CAB-LA is more effective than event-driven oral PrEP (aOR = 1.48, 95%CI = 1.10-1.99). This analysis demonstrated Australian GBMSM have a diverse range of preferences of PrEP options, and access to newer options is needed to increase HIV prevention coverage.

Indexed as

Anti-HIV AgentsHIV InfectionsHomosexuality, MalePre-Exposure ProphylaxisPyridonesSexual and Gender MinoritiesAdultAustraliaCross-Sectional StudiesDelayed-Action PreparationsDiketopiperazinesHumansInjectionsMaleMiddle AgedSurveys and QuestionnairesAnti-HIV AgentscabotegravirDelayed-Action PreparationsDiketopiperazinesPyridonesCabotegravirEvent-driven PrEPLenacapavirMen who have sex with menPre-exposure prophylaxis

Identifiers

PMID41243079

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.